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ABSTRACT 
Aims: To evaluate the difficulties met in the care of pregnant women with toxoplasmosis diagnosis in antenatal 
care services. Methods: Longitudinal prospective study with 262 pregnant women referred to the Toxoplasmosis 
Clinic at Instituto de Pesquisa Clínica Evandro Chagas-Fundação Oswaldo Cruz, between January 2005 and July 
2009. Results: Most women (91.2%) were in the second and third trimesters of pregnancy, and 81.3% were referred 
by public health services. The average delay was 113.4 days in the collection of the first sample for serological tests in 
antenatal care, 52.1 days for referral and 160.6 days in starting treatment. Younger women (P=0.03) and those from the 
public health system were referred later (P<0.05). Treatment was initiated at the origin for only 16% of the pregnant 
women, and 5% of these did not receive the recommended dose of spiramycin. At the Reference Center there was a 
low rate of confirmation of the serological tests performed in the health services of origin. It was found that 12.6% 
of pregnant women with an initial diagnosis of acute toxoplasmosis were susceptible to infection by Toxoplasma 
gondii. These tests were considered false positives. Conclusions: This study highlights the difficulties met in the 
management of pregnant women with toxoplasmosis in the antenatal care, including the quality of diagnostic tests 
and the need for greater emphasis on continuing education of health professionals.
Keywords: TOXOPLASMOSIS, CONGENITAL; TOXOPLASMOSIS/diagnosis; PRENATAL DIAGNOSIS; PRENATAL CARE; 
PREGNANCY COMPLICATIONS, INFECTIOUS; REFERENCE CENTERS; LONGITUDINAL STUDIES; PROSPECTIvE 
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RESUMO
Objetivos: avaliar as dificuldades encontradas no atendimento de gestantes com diagnóstico de toxoplasmose 
por parte de serviços de atendimento pré-natal. Métodos: estudo longitudinal, prospectivo, com 262 gestantes 
encaminhadas ao Ambulatório de Toxoplasmose do Instituto de Pesquisa Clínica Evandro Chagas-Fundação Oswaldo 
Cruz, entre janeiro de 2005 e julho de 2009. Resultados: a maioria das gestantes foram encaminhadas no segundo 
ou terceiro trimestre de gestação (91,2%) e por serviços públicos de saúde (81,3%). O tempo médio de demora na 
coleta de sangue para os testes sorológicos no pré-natal foi de 113,4 dias. Houve demora média de 52,1 dias para o 
encaminhamento e 160,6 dias para o início do tratamento. Mulheres mais jovens (P=0,03) e aquelas provenientes do 
sistema público de saúde (P<0,000) foram encaminhadas mais tardiamente. O tratamento foi iniciado na origem em 
apenas 16% das gestantes, e 5% destas não receberam a dose preconizada de espiramicina. No Centro de Referência 
houve baixa confirmação dos testes sorológicos realizados nos serviços de saúde de origem. Constatou-se que 12,6% 
das gestantes com diagnóstico inicial de toxoplasmose aguda eram suscetíveis à infecção por Toxoplasma gondii, sendo 
os testes considerados falso-positivos. Conclusões: este estudo destaca dificuldades observadas no manejo de gestantes 
com toxoplasmose por parte do atendimento pré-natal da rede básica de saúde, incluindo a atenção quanto à qualidade 
dos testes diagnósticos e a necessidade de maior ênfase na educação continuada dos profissionais de saúde.
Descritores: TOXOPLASMOSE; TOXOPLASMOSE CONGêNITA/diagnóstico; DIAGNóSTICO PRé-NATAL; CUIDADO PRé-
NATAL; COMPLICAÇÕES INFECCIOSAS NA GRAvIDEZ; CENTROS DE REFERêNCIA; ESTUDOS LONGITUDINAIS; 
ESTUDOS PROSPECTIvOS; FEMININO; GRAvIDEZ.  Sci Med. 2010;20(1):40-44  41
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INTRODUCTION
Congenital  toxoplasmosis  occurs  secondary  to 
transplacental  transmission  of  Toxoplasma  gondii   
(T.  gondii)  during  the  period  of  maternal  acute 
infection.1-3 It is characterized by a broad spectrum 
of clinical manifestations, with neurological, ocular 
and systemic involvement. Although most newborns 
with congenital infection show no manifestations of 
infection at birth, 85% of these will develop visual 
impairment in the first two years, and 55% will present 
neurological disorders.4-6 The frequency of vertical 
transmission  is  low  in  the  first  trimester  (3-9%) 
increasing at the end of pregnancy to 60-81%. The 
severity of fetal damage is higher in the beginning of 
pregnancy (34-85%) and lower at the end of pregnancy 
(4-17%).7    Serological  tests  such  as  the  detection   
of anti-T gondii IgG and IgM, associated with the   
IgG-avidity test  8-11 have been the main means of 
diagnosis used in clinical practice.  Seroconversion of 
IgG, a significant increase in IgG titers in paired tests 
and the appearance of IgM, are considered indicators 
of  acute  infection.  Since  toxoplasmosis  is  usually 
subclinical, its diagnosis depends on the detection of 
serological  markers  during  pregnancy.  Serological 
diagnosis is a challenge for professionals involved in 
management of pregnant women. False-positive IgM 
or residual IgM persistence are confounding factors in 
the serological diagnosis of toxoplasmosis.7,12 Testing 
of IgG avidity is a time counter, and the diagnosis 
of recent infection based on the low avidity of IgG 
is  particularly  useful  when  performed  in  the  first 
trimester of pregnancy. Despite the absence of clinical 
trials, there is consensus that the use of antiparasitic 
drug  may  reduce  the  risk  of  transmission  or  the 
severity of fetal injury, especially if given early in 
pregnancy.13-16
The Toxoplasmosis Outpatient Clinic at Instituto 
de Pesquisa Clínica Evandro Chagas (IPEC)/Fundação 
Oswaldo Cruz (Fiocruz) is a reference in monitoring 
cases of toxoplasmosis, receiving pregnant women 
from various health units in Rio de Janeiro. In order 
to describe some difficulties in the care of pregnant 
women referred with the diagnosis of toxoplasmosis, 
the  authors  studied  the  cases  of  pregnant  women 
seen at the clinic between January 2005 and July 
2009, referred with positive IgM for toxoplasmosis, 
regarding:  (a)  the  referral  source  and  referral  of 
patients with prescription; (b) delay in the performance 
of serological tests, in referral to the reference service 
and in beginning of treatment; and (c) existence of tests 
with discordant results or false-reactive, performed in 
the services of origin. 
METHODS
A prospective longitudinal study was conducted 
at the Toxoplasmosis Outpatient Clinic at the IPEC/
Fiocruz, Rio de Janeiro. This study included the totality 
of women with suspicion of toxoplasmosis acquired 
during pregnancy (positive anti-T. gondii IgM) referred 
to the clinic between January 2005 and July 2009. The 
study was approved by the Committee on Ethics in 
Research of IPEC/Fiocruz.
The patients were seen at Toxoplasmosis Out- 
patient  Clinic  at  IPEC/Fiocruz,  Reference  Center 
for  Toxoplasmosis  (RC),  according  to  the  same 
clinical-epidemiological protocol. Serological tests 
for toxoplasmosis were made in the RC using an 
enzyme-linked immunosorbent assay (ELISA capture 
Biokit,  Barcelona,  Spain)  and  an  enzyme-linked 
fluorescent assay (ELFA) (VIDAS, bioMérieux S.A., 
Lyon,  France).  In  case  of  positive  IgM  samples,   
testing was performed for IgG avidity to T. gondii 
(vIDAS Toxo-IgG Avidity, bioMérieux, Marcy-l’Etoile,   
France).
Patients were clustered according to age group 
(<20, 20-29, and ≥30 years), origin (health care system, 
public or private, that referred them to the RC), and 
trimester of pregnancy at first visit in the RC (first 
gestational trimester: <12 weeks, second gestational 
trimester: 12 to 24 weeks, third gestational trimester: > 
24 weeks). variables were created to estimate changes 
in time (in days), such as: delay in serological tests 
(difference  between  the  beginning  of  pregnancy, 
identified by date of last menstrual period, and date 
of collection of first sample for antenatal serological 
tests);  delay  in  treatment  (difference  between  the 
date of last menstrual period and the beginning of the 
treatment for toxoplasmosis); and delay in referral (time 
between the date of collection of blood for serological 
tests in antenatal care and the date of the first visit at   
the RC).
Data  were  compiled  in  the  statistical  program 
SPSS version 11 (SPSS Inc., Chicago, USA). Data 
analysis was performed with Stata software version 
8.2,  2005  (Stata  Corp.,  College  Station,  USA). 
Statistical  analysis  estimated  confidence  intervals 
(CI) of 95% for means and time differences. Chi-
square test was used in bivariate distributions, with the 
criterion of statistical significance being P value less   
than 0.05.
RESULTS
The study included 262 pregnant women, aged 
between 12.9 and 45.5 years (25.4±6.7). Most of them 42  Sci Med. 2010;20(1):40-44
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(81.3) were referred by public health services, and 
91.2% were in second and third trimesters of pregnancy 
when referred (Table 1). Twenty two patients presented 
low IgG avidity. Treatment was initiated at the origin in 
42 women (16%), and 13 (5%) of these did not receive 
the recommended dose of spiramycin. No patient was 
prescribed  with  sulfadiazine,  pyrimethamine  and 
folinic acid.
Table 1. Age group, origin and trimester of gestation 
of  pregnant  women  referred  with  diagnosis  of  acute 
toxoplasmosis to the Toxoplasmosis Outpatient Clinic at 
Instituto de Pesquisa Clínica Evandro Chagas-Fundação 
Oswaldo Cruz, 2005-2009
Variables n %
Age group (years)
<20 64 24.4
20-29  138 52.7
> 30 60 22.9
Total 262 100.0
Origin
Public system 213 81.3
Private system 49 18.7
Total 262 100.0
Trimester of gestation
First 23 8.8
Second 137 52.3
Third 102 38.9
Total 262 100.0
Younger  women  (P=0.03)  and  those  from  the 
public health system (P<0.000) were sent later to the 
RC (Table 2), and most young women were referred 
by public health units (P=0.03) (Table 2). Overall, 
the pregnant women took an average time of 113.4 
days (95% CI: 106.9-118.8) to collect the serological   
tests in prenatal care, 52.1 days (95% CI: 47.7-56.6)   
to  be  referred  to  the  RC  and  160.6  days  (95%   
CI: 153.6-167.6) to start treatment for toxoplasmosis. 
Pregnant women from the public health units took 
24.8 days longer to perform serological tests for toxo- 
plasmosis and 50.3 days longer to start the treatment, 
compared  to  those  referred  by  private  physicians 
(Table 3).
Of  the  total  of  262  pregnant  women  with 
positive anti-T. gondii IgM during prenatal care, 
136 (52%) had positive or indeterminate IgM at 
the RC. However, false positive results were found 
in 126 cases (48%) and among these, 33 women 
(12.6% of those initially suspected of having acute 
toxoplasmosis) were susceptible to toxoplasmosis 
(IgG and IgM negative) (Table 4). 
Table 2. Gestational trimester of referral according to the health system of origin or the age group of pregnant women 
referred with diagnosis of acute toxoplasmosis to the Toxoplasmosis Outpatient Clinic at Instituto de Pesquisa Clínica 
Evandro Chagas-Fundação Oswaldo Cruz, 2005-2009 
Gestational trimester
Origin
Total
Age group
Total
Private Public > 20 years 20-29 years ≥ 30 years
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
First 15 (30.6)   8 (3.8) 23 (8.8) 1 (1.6) 13 (9.4)   9 (15.0)  23 (8.8)
Second 26 (53.1) 111 (52.1) 137 (52.3) 30 (46.9)   75 (54.3) 32 (53.3) 137 (52.3)
Third   8 (16.3)   94 (44.1) 102 (38.9) 33 (51.6)   50 (36.2) 19 (31.7) 102 (38.9)
Total 49 (100.0) 213 (100.0)   262 (100.0)   64 (100.0)   138 (100.0)   60 (100.0)   262 (100.0)
Pearson’s chi-square (2) = 40.6474, p<0.0005   Pearson’s chi-square (4) = 10.6841, p=0.030
Table 3. Average time of delay between first serological tests and beginning of treatment 
for toxoplasmosis in pregnant women referred with diagnosis of acute toxoplasmosis to the 
Toxoplasmosis Outpatient Clinic at Instituto de Pesquisa Clínica Evandro Chagas-Fundação 
Oswaldo Cruz, 2005-2009
Origin Delay in serological tests 
(days) 95% CI* Delay in treatment 
(days) 95% CI*
Public system 118.3 111.5-125.1 170.0 162.7-177.4
Private system 93.5 77.0-109.9 119.7 104.1-135.4
Difference between public 
and private
24.8 9.0 -40.7 50.3 33.4-67.2
* CI = confidence interval  Sci Med. 2010;20(1):40-44  43
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DISCUSSION
Despite the high prevalence of T. gondii infection, 
control and management of prenatal transmission are 
not yet standardized in Brazil.17,18 The main strategy 
for the prevention of this infection with potentially 
tragic  outcomes  is  still  the  health  education,  and 
prenatal  serological  screening  should  be  initiated 
early.  Most  of  the  women  studied  (91.2%)  were 
in second or third trimester of pregnancy. The late 
performance of serological tests for toxoplasmosis 
led to a delay in referral and care in the RC. Thus, the 
treatment for toxoplasmosis was initiated on average 
in the fifth month of pregnancy. The delay between 
the average time of testing and the average time of 
initiation of treatment points to another problem of the 
health system: the excessive time delay in accessing 
the results of serological tests, therefore influencing 
the delay in referral to the RC. This was especially 
observed among pregnant women referred by public 
health units. In these cases, confounding factors, such 
as educational level and age, may interfere with the 
quality of prenatal care.19 The delay observed on the 
initiation of prenatal care and the performance of 
serological tests in public health facilities in Rio de 
Janeiro was consistent with that seen in other regions 
of Brazil and Latin America.20-22 
Spiramycin  was  prescribed  in  the  services  of 
origin  in  only  11%  of  cases.  The  misinformation 
about the management of toxoplasmosis in pregnant 
women by physicians who perform prenatal care has 
already been noted by other authors.23,24 Despite recent 
controversy regarding the effectiveness of spiramycin 
in preventing congenital infection, it has been shown 
that treatment is effective when administered early.14,16 
Due to the absence to date of randomized controlled 
clinical trials, spiramycin is still the recommended 
drug  for  the  treatment  of  acquired  toxoplasmosis 
during pregnancy, especially in the first trimester. 
Sulfadiazine,  pyrimethamine  and  folinic  acid  are 
indicated in infections acquired later, and when there 
is proven fetal infection.14 It is beyond the scope of 
this paper reporting the clinical management in each 
case, however it is noteworthy the fact that no pregnant 
women have been given this regimen at the services of 
origin, even when diagnosed later.
False-positive  anti-T.  gondii  IgM  results  are 
described by several authors.13,25 Since IgM antibodies 
can remain positive for many months or even years 
after acute infection,26,27 a negative result virtually 
remove the possibility of recently acquired infection. 
Once external serological tests were performed by 
several  laboratories,  accuracy  of  interpretation  of 
those results was impaired. Thus, a high proportion 
of pregnant women who attended RC had discordant 
results in relation to the IgM test. Many pregnant 
women who were susceptible to infection by T. gondii 
were misdiagnosed as suffering from an acute infection, 
with potential fetal damage. Besides the emotional 
stress  to  which  these  women  were  unnecessarily 
subjected, there was an unnecessary expense with the 
drugs for treatment. The average unit cost of 500 mg 
of spiramycin was $1.00, which resulted in per capita 
daily $6.00 with the recommended dose of 3 g/day.14 
Furthermore, we assume that a lot of patients were 
overtreated due to a false diagnosis of toxoplasmosis 
acquired  during  pregnancy.  All  patients  received 
spiramycin at the first medical evaluation, switched to 
sulfadiazine, pyrimethamine and folinic acid in those 
with positive IgM and low IgG avidity or evidence of 
fetal infection.
We conclude that both health systems, public and 
private, had difficulties in the care of pregnant women, 
with late diagnosis, referral and treatment, and that it 
Table 4. Serological status to Toxoplasma gondii infection in pregnant women referred to the Toxoplasmosis Outpatient 
Clinic at Instituto de Pesquisa Clínica Evandro Chagas-Fundação Oswaldo Cruz (Reference Center), according to tests 
performed in the laboratories of prenatal care (source) and in the the Reference Center, 2005-2009
Serology in origin
Serology in the Reference Center 
IgM(+)/IgG(+) IgM(+)/IgG(-) IgM(I)/IgG(+) IgM(-)/IgG(+) IgM(-)/IgG(-) Total
n (%) n (%) n (%) n (%) n (%) n (%)
IgM(+) and IgG(+) 110 (46.2)  3§ (1.2) 13 (5.5)  92 (38.7) 20 (8.4)   238 (100.0)
IgM(+) and IgG(-)     4 (21.0)  1† (5.3)   1 (5.3)   0 (0.0)   13 (68.4)     19 (100.0)
IgM(+) without IgG     2 (40.0)  0  (0.0)     2 (40.0)     1 (20.0)   0 (0.0)       5 (100.0)
Total 116 (44.3)  4  (1.5) 16 (6.1)  93 (35.5)   33 (12.6)   262 (100.0)
(I) = indeterminate, (+) = positive, (-) = negative;  § Two patients did not return to the Reference Center for subsequent visits and serological 
confirmation, and one patient remained IgM(+) near cut-off without raising titles in paired samples collected one month apart. † One patient remained 
IgM(+) near cut-off /IgG(-) in paired samples collected one month apart, sugesting indeterminate IgM.44  Sci Med. 2010;20(1):40-44
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is necessary to implement measures of early assistance 
in order to contribute to the prevention of congenital 
toxoplasmosis.  Knowledge  about  the  difficulties 
encountered  by  health  professionals  and  health 
systems with regard to the approach of toxoplasmosis 
during the prenatal period may help in the discussion 
about control and management of toxoplasmosis in 
pregnancy. Congenital toxoplasmosis is a preventable 
disease and the authors emphasize the importance 
of  early  prenatal  serological  tests,  and  preventive 
measures when necessary, in order to avoid a dramatic 
fetal disease.
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